Suppliers and packagers for JAVADIN

JAVADIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Azurity	JAVADIN	clonidine hydrochloride	SOLUTION;ORAL	220256	NDA	Azurity Pharmaceuticals, Inc.	24338-115-01	1 BOTTLE in 1 CARTON (24338-115-01) / 250 mL in 1 BOTTLE	2025-10-23

Suppliers for the Pharmaceutical Drug JAVADIN

Last updated: February 20, 2026

Who Are the Major Suppliers of JAVADIN?

JAVADIN is the brand name for dabigatran etexilate, an oral anticoagulant used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis (DVT), and pulmonary embolism (PE). The drug is marketed by Boehringer Ingelheim.

Key Suppliers and Manufacturing Sources

• Boehringer Ingelheim: As the patent holder and sole marketer, Boehringer Ingelheim controls the production and distribution of JAVADIN. It manages global manufacturing facilities, predominantly located in Europe and North America, with licensed suppliers worldwide.

• Active Pharmaceutical Ingredient (API) Suppliers:

  • The API, dabigatran etexilate, is procured from multiple suppliers to ensure supply security and cost management. Major API suppliers include Chinese manufacturers, with some from India and Europe.
  • These suppliers have undergone regulatory validation processes to meet quality standards set by agencies such as the FDA, EMA, and other national regulators.

• Formulation and Final Product Manufacturing:

  • The finished drug is produced through contract manufacturing organizations (CMOs). Boehringer Ingelheim often partners with CMOs to handle formulation, packaging, and distribution.
  • Facilities involved include plants in Europe, North America, and Asia, subject to Good Manufacturing Practice (GMP) standards.

API Supplier Market Structure

Supplier Location	Regulatory Status	Estimated Market Share	Notes
China	GMP approved	~50%	Largest API supplier for dabigatran etexilate globally, with several registered producers.
India	GMP approved	~25%	Increasing presence, serving domestic and export markets.
Europe	GMP approved	~15%	Select European manufacturers with long-standing quality track records.
Other (USA, Singapore)	GMP approved	~10%	Smaller players providing specialty or high-quality APIs.

Regulatory Status and Approvals

• FDA: Approved in 2010 for stroke prevention in atrial fibrillation (AF).
• EMA: Approved in 2011, also for DVT and PE indications.
• Other markets: Similar approvals granted in Canada, Japan, Australia, and select Asian countries, often with local manufacturing or approved API sources.

Supply Chain Considerations

• Dependence on Asia: The API supply chain for JAVADIN relies heavily on Chinese and Indian API manufacturers, which introduces geopolitical and regulatory risks.
• Manufacturing Capabilities: Boehringer Ingelheim maintains strategic partnerships with multiple CMOs to mitigate supply disruptions.
• Generic Market Entry: Patent expiry scheduled for 2027-2028 could lead to increased licensing agreements and competition, expanding supplier diversity.

Future Supply Dynamics

• Expected growth in dabigatran-related indications and market penetration.
• Potential shifts toward more regional API production to reduce reliance on Asia due to supply chain security concerns.
• Regulatory developments impacting manufacturing standards, quality audits, and international harmonization may influence supplier participation.

Summary

Boehringer Ingelheim is the exclusive marketer of JAVADIN, with the drug produced under global partnerships. The core API sources stem predominantly from Chinese manufacturers, with growing contributions from India and Europe. Supply chain security is maintained through multiple suppliers and strategic manufacturing alliances.

Key Takeaways

• Boehringer Ingelheim controls JAVADIN distribution and manufacturing.
• The main API suppliers are located in China, India, and Europe.
• The Asia-based API supply chain accounts for approximately 75% of raw material sourcing.
• Regulatory approvals span North America, Europe, and Asia, with ongoing patent expirations influencing market dynamics.
• Supply chain risks include geopolitical issues, quality assurance, and potential impacts from patent expiry and competition.

FAQs

1. Will generic versions of dabigatran etexilate increase availability?
Yes, patent expiration around 2027-2028 is expected to open the market to generics, increasing supply options and decreasing prices.

2. Are there alternate sources for API production for JAVADIN?
Current API sourcing is concentrated, but new suppliers may enter the market before patent expiry to prepare for generic competition.

3. How does supplier quality affect the drug’s market?
Quality assurance from suppliers directly impacts regulatory compliance and product safety, influencing supply stability.

4. Are there regional differences in JAVADIN supply?
Yes, distribution varies based on local approvals, manufacturing licenses, and supply chain infrastructure, with higher concentrations in Europe and North America.

5. What risks might disrupt JAVADIN supply?
Regulatory changes, geopolitical tensions, raw material shortages, and manufacturing disruptions pose supply risks.

---

References

1. Boehringer Ingelheim. (2023). JAVADIN (dabigatran etexilate) prescribing information.
2. U.S. Food and Drug Administration. (2010). FDA approves new anticoagulant for stroke prevention.
3. European Medicines Agency. (2011). EMA approves dabigatran for atrial fibrillation treatment.
4. IQVIA. (2022). Global API Market Analysis.
5. U.S. Patent and Trademark Office. (2023). Patent status for dabigatran etexilate.